ROSGQ (ROSGQ) Stock Price & Analysis
ROSGQ (ROSGQ) rose 0.00% to USD 0 as of June 10, 2026 at 13:38 UTC, according to Nexqual real-time market data.
ROSGQ last closed at USD 0; the session ranged USD 0–0 on volume of 1,642 shares. Market capitalization is $592, with a 52-week range of USD 0–0 (PNK). Source: Nexqual, June 10, 2026 at 13:38 UTC.
Key Statistics (as of June 10, 2026 at 13:38 UTC)
| Price | USD 0 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 0 |
| Open | USD 0 |
| Day Range | USD 0 – 0 |
| 52-Week Range | USD 0 – 0 |
| Volume | 1,642 shares |
| Market Cap | $592 |
| Exchange | PNK |
Technical Analysis (ROSGQ)
Nexqual's technical model rates ROSGQ "STRONG SELL" based on 0 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 13:38 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 100 (overbought) |
| vs SMA50 | Below (USD 0) |
| MACD | 0 (negative) |
Analyst Ratings (ROSGQ)
Wall Street analysts rate ROSGQ "None", per Nexqual as of June 10, 2026 at 13:38 UTC.
| Consensus Rating | None |
|---|
Earnings (ROSGQ)
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2016-12-31 | USD -2.71 vs est -1.38 ▼ miss |
| 2016-09-30 | USD -2.16 vs est -2.04 ▼ miss |
| 2016-06-30 | USD -1.92 vs est -2.08 ▲ beat |
| 2016-03-31 | USD -2.21 vs est -2.4 ▲ beat |
Source: Nexqual, June 10, 2026 at 13:38 UTC.
Financials & Fundamentals (ROSGQ)
| Total Revenue | $2.86M |
|---|---|
| Revenue Growth (YoY) | +115.30% |
| Gross Margin | +33.65% |
| Operating Margin | -157.59% |
| Profit Margin | +0.00% |
| ROE | -137.96% |
| Debt / Equity | 222.84 |
| Current Ratio | 2.09 |
| Total Cash | $1.32M |
| Total Debt | $2.45M |
| Free Cash Flow | $-6.04M |
Source: Nexqual, June 10, 2026 at 13:38 UTC.
Financial Health Score (ROSGQ)
Nexqual rates ROSGQ's overall financial health "Weak" across five dimensions, as of June 10, 2026 at 13:38 UTC.
| Growth | Solid — Revenue +12% YoY (annual) |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Weak — $1M cash vs $2M debt |
| Cash Flow | Weak — FCF negative: -$6M, burning cash |
| Efficiency | Critical — ROE -138%, ROA -60.2% |
Ownership (ROSGQ)
| Insider Ownership | +0.00% |
|---|---|
| Institutional Ownership | +0.00% |
| Shares Outstanding | 5.93M |
| Float | 2.18M |
| Short % of Float | +5.05% |
Source: Nexqual, June 10, 2026 at 13:38 UTC.
Leadership (ROSGQ)
ROSGQ is led by Douglas Sites, Executive Vice President of Sales & Marketing, per Nexqual as of June 10, 2026 at 13:38 UTC.
| Executive Vice President of Sales & Marketing | Douglas Sites |
|---|---|
| Deputy Chairman of the Scientific Advisory Board | Zvi Bentwich |
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| PZRXQ | PHASERX INC | USD 0 | ▲ 0% |
| RGDXQ | RESPONSE GENETICS INC | USD 0 | ▲ 0% |
| PFND | PATHFINDER CELL THERAPY INC | USD 0 | ▲ 0% |
| TNGNQ | TENGION INC | USD 0 | ▲ 0% |
| NSTM | NovelStem International Corp. | USD 0.01 | ▼ 70% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 13:38 UTC. This page is informational and not investment advice.